synthase (iNOS) gene transcription. Cytosolic PLA 2 , PGs and NO have been shown to modulate cell survival by either inducing or inhibiting lymphocyte PCD (2) (3) (4) . In previous studies, it was demonstrated that GCH-induced mouse thymocyte apoptosis relied on the activation of early biochemical events promoting cell death induction (5) and this signalling cascade triggered after activated GR-associated Src Kinase activation (6) (7) . In particular, it was shown that dexamethasone (Dex), a synthetic GCH, after GR-binding, rapidly activated a signalling pathway causing the sequential activation of a phosphatidylinositol-specific phospholipase C (PI-PLC) and the acidic sphingomyelinase (aSMase). The consequent ceramide generation appeared to be responsible for the downstream activation of the caspase cascade and cell apoptosis (5) . The inhibition, at any level, of this signalling pathway also abolished Dex-induced apoptosis. Furthermore, the observation that transcription or protein synthesis inhibitors suppress GCH-induced thymocyte apoptosis without affecting GCH-induced PI-PLC, aSMas.e and caspase activation, supports the notion that GCH and others steroid hormones regulate intracellular signalling pathways and cellular functions independently from their well-known transcriptional action (5) .
Glucocorticoid-induced apoptosis of immature thymocytes is a classical in vivo model of apoptosis, but the mechanisms involved are not completely understood (8) . Activated cytosolic PL~plays an important role in mediating arachidonic acid (AA) release from the sn-2 position of membrane bound phospholipids (9) . The important role ofAA in cellular functions and activation requires a tight control of its level: consequently, cPLA 2 expression and activity are subject to a complex mechanism of regulation at a transcriptional and post-traslational level (10) (11) . cPLA 2 is constitutively expressed in most cell types: however, extracellular stimuli, such as interieukin (IL)-I, tumor necrosis factor-a (TNFa), monocyte colony-stimulating factor (M-CSF) and epidermal growth factor (EGF), have been shown to induce the prolonged protein expression of cPLA z in various cell lines (12) . The increase in cPLA 2 protein expression is a result of enhanced translation of cPLA 2 mRNA or prolonged half-life of cPLA z protein. Suppression of cPLA 2 expression can be mediated by GCH, like dexamethasone (12) . Interestingly, the fact that cPLĩ s constitutively expressed might render cPLA z capable ofrapidly responding to physiological stimuli, whereas the increase in cPLA 2 expression and activity might be involved in development and differentiation. cPLA 2 is almost ubiquitously expressed: one remarkable exception seems to be represented by mature T and B lymphocytes, whereas cPLA 2 is expressed in thymocytes and immature B cells (2, (13) (14) . However the presence and the role of different isofonns of PLA 2 in T-cell activation and proliferation are controversial. In a recent investigation, in fact, it has been observed that Jurkat T-cells constitutively express the mRNAs which encode for four different PLA 2 isoforms (type-IB, -v, IV and -VI): among these isoforms, secreted (type IB and type V) as well as cytosolic Ca 2 +indipendent (type VI) PLAzs seem to play a critical role in T-cell proliferation (14) . These results are in agreement with the findings of Boilard and Surette, who identified type IV PLA 2 in human T-Iymphocytes. Roshak et al. reported that iPLA z is expressed in human peripheral blood lymphocytes and Jurkat T-cells and that it plays an important role in 'I-cell proliferation: its depletion by antisense treatment resulted in marked suppression of ceIl division (2) . These data provide the evidence that iPL~is a key participant in the molecular processes regulating lymphocyte division, thus suggesting that the expression and the activity of cPLA z are incompatible with the function of mature lymphocytes.
In the present study we carried out experiments to evaluate the possible role of cPLA 2 in thymocyte survival, and the possible involvement of cPLA z inhibition in Dex-induced apoptosis.
MATERIALS AND METHODS

Reagents
Dexamethasone (Dex), Monensin, and pbromophenacyl bromide (pBPB) were purchased from Sigma Chemical Co (St. Louis, MO, USA). Arachidonyl trifluoromethyl ketone (AACOCF3), palmitoyl trifluoromethyl ketone (PACOCF3) and bromoenol lactone (BEL), were purchased from Cayman Chemical (Ann Arbor, USA). U73122 was from Calbiochem (La Jolla, CA, USA).
Thymocyte Preparation and Culture
Mouse thymocytes were prepared from 4-to 6-weekold C3H/HeN mice and enriched by passage through nylon wool columns. Cells were then incubated for different times in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mmol/L glutamine, 100 IU/ml penicillin, 100 ug/ml streptomycin at 37°C in a 5% CO 2 atmosphere and treated as reported below.
Apoptosis evaluation by propidium iodide solution
Apoptosis was measured by flow cytometry as described elsewhere. After culturing, cells were centrifuged and pellets were gently resuspended in 1.5 ml hypotonic propidium iodide solution (PI 50 ug/rnl in 0.1% sodium citrate plus 0.1% Triton X-IOO, Sigma, St. Louis, MO, USA). Tubes were kept at 4°C in the dark overnight (15) . The PI-fluorescence of individual nuclei was measured by flow cytometry with standard FACScan equipment (Becton Dickinson, Mountain View, CA). Nuclei traversed the light beam of a 488 nm Argon laser. A 560 nm dichroid mirror (DM 570) and a 600 nm band pass filter (band width 35 nm) were used to collect the red fluorescence due to PI DNA staining, and data were recorded in logarithmic scale in a Hewlett Packard (HP 9000, model 310; Palo Alto, CA) computer. The percentage ofapoptotic cell nuclei (sub-diploid DNA peak in the DNA fluorescence histogram) was calculated with specific FACScan research software (Lysis II).
Phospholipase A] (PLA;) activity assays
Thymocytes (5 x 10 6 ) were incubated, with or without Dex (10-7 M), RU486 (10-6 M), AACOCF3 (10 11M), pBPB (20 11M), PACOCF3 (10 11M) and BEL (5 11M) in different kinetics (1-60 min). Incubation was stopped by centrifugation at 500 x g for 1 min at 4°C. Cell pellets were resuspended in 300 III of 250 mM Tris-HCI buffer pH 8.5, containing 10 11M PMSF, I ug/ml leupeptin, I Ilg/ ml pepstatin, I ug/rnl aprotinin, 5 ug/ml soybean trypsin inhibitor, 100 11M bacitracin and 1 mM benzamidine. Cells were lysed by sonication and protein concentrations were determined using a Bio-Rad protein assay. Radio-labelled PC vesicles were prepared by.sonicating the radio-labelled phospholipid L-3-phosphatidylcholine, l-stearoyl-2-[ 1-14C] arachidonyl (25 IlCi/ml; specific activity 55.0 mCi/ mmol; Amersham, Little Chalfont, UK) for the detection of released AA, in 50 mM Tris-HCI buffer pH 8.5, containing fatty acid-free BSA (0.01%) in an ice bath (5 min, 5 W and 80% output). Vesicles, resuspended at I 11M in the reaction buffer (50 mM Tris-HCI buffer pH 8.5, 5 mM CaCI 2 , 5 mM MgCI 2 , 0.0 I% fatty acid-free BSA), reacted with whole cell lysate (60-100 ug) and were incubated at 37°C for I h; the reaction was stopped by the addition of 250 IIIchloroform:methanol:acetic acid (4:2: 1, by vol). To separate the organic from the aqueous phase, 250 III of H 20, 250 III of CHCI 3 and 100 III of Kp were added, and the mixture was centrifuged at 10,800 g in a microfuge for 5 min. The organic phase was removed, dried under nitrogen, resuspended in 200 III chloroform and applied to a silica gel TLC plate (Merck, Darmstadt, Germany), with an automatic applicator (Linomat IV; CAMAG, Muttenz, Germany). Samples were chromatographed in chloroform:methanol:acetic acid:water (100:60: 16:8, by vol) to separate the labelled product of PLA 2 activity. Authentic standards were co-chromatographed with the lipid extracts to locate the compounds of interest. The radioactive spots were visualized by autoradiography, scraped from the plate and counted by liquid scintillation. Blank values obtained from controls lacking cell proteins were subtracted from the experimental values. PLA 2 activity was quantified by the release of AA from PC and expressed as picomoles of AA produced/mg protein.
Measurement ofAA release from living thymocytes
Mouse thymocytes (5xI0 6/ml) were labelled for 18 h with 0.1 IlCi/ml [5, 6, 8, 9, 11, 12, 14 , IVH(N)]Arachidonic acid (specific activity 215 Ci/mmol; PerkinElmer Life and Analytical Sciences, Boston, MA) in complete medium. Cells were washed twice with complete medium supplemented with 0.1% (wt/vol) fatty acid-free bovine serum albumine and then incubated with or without Dex (10-7 M) for the indicated times (1-60 min). Incubations were stopped at appropriate time points by centrifugation at 500 x g for 5 min. at 4°C and the supernatants were then collected and their radioactivity was determined by liquid scintillation counting. Cells were lysed in 0,1% Triton X-100 for 5 min and also counted by liquid scintillation for determining the total cellular radioactivity.
Phosphatidylinositol-specific phospholipase C (PI-PLC) and phosphatidycholine specific phospholipase C (PC-PLC) activity assays
To evaluate the ability of Dex and AACOCF3 to affect PI-PLC enzyme activity, thyrnocytes were treated for the indicated times with Dex (10-7 M) or AACOCF3 (10 11M) and, in some experiments, in presence or in absence of the PI-PLC inhibitor, U73122 (2.5 11M) (5) . Treatments were stopped by immersion of samples in methanol/dry ice (-70°C) for 10 sec followed by centrifugation at 4°C in a microfuge. The pellets were then resuspended in 250 roM Tris-HCI buffer, pH 7.4, containing 10 11M PMSF, 100 11M bacitracin, I roM benzamidine, I 11M aprotinin, 10 11M leupeptin, 10 11M pepstatin and 5 ug/ml soybean trYpsin inhibitor. Cells were lysed by sonication with a cell sonifier. PI-PLC activity was determined in vitro by their ability to hydrolyse 14C_PI vesicles to generate diacylglycerol (DAG). Radiolabeled PI vesicles were obtained by sonicating L-3-phosphatidylinositol-lstearoyl-Zjr'Cjarachidonyl, (10 IlCi/ml; specific activity 48.0 mCi/mmol, NEN Life Science Products, Inc. Boston, MA) in 20 roM Tris-HCI, pH 7.4, containing 0.0 I% fatty acid free-BSA in an ice bath (5 min, 5W, and 80% output). PC-PLC activity was determined in vitro by their ability to hydrolyse 14C_PC vesicles to generate diacylglycerol (DAG). Radiolabeled PC vesicles were obtained by sonicating L-3-phosphatidylcholine, I-stearoyl-2-[ 1-14C] arachidonyl (25 f.lCi/ml; specific activity 55.0 mCii mmol; Amersham, Little Chalfont, UK) in 20 mM Tris-HCI, pH 7.4, containing 0.0 I% fatty acid free-BSA in an ice bath (5 min, 5W, and 80% output). Vesicles were resuspended at 10 uM in the reaction buffer (50 mM Tris-HCI, pH 7.4, 5 mM CaCI 2 , 5 mM MgCI 2 , 0.01% fatty acid free-BSA). Whole cell Iysates (50-100 ug proteins) were added with 250 ul vesicle containing reaction buffer, incubated at 37°C for I h; the reaction was stopped by the addition of 250 ul chlorofonn:methanol:acetic acid (4:2:1, by vol). To separate the organic from the aqueous phase, 250 ul of H 20, 250 ul of CHCl l and 100 ul of KCI were added, and the mixture was centrifuged at 10,800 g in a microfuge for 5 min. The organic phase was removed, dried under nitrogen, resuspended in 200 ul chloroform and applied to a silica gel TLC plate (Merck, Darmstadt, Germany), with an automatic applicator (Linomat IV; CAMAG, Muttenz, Germany), Samples were chromatographed in petroleum ether:diethyl ether:acetic acid (70:30: I, by vol) to separate the parent PI or PC phospholipids from the product ofPI-PLC or PC-PLC, i.e. DAG. Authentic standards were co-chromatographed with the lipid extracts to locate the compounds of interest by exposure to iodine vapor. Radioactive spots, visualized by autoradiography and corresponding to standards, were scraped from the plate and counted by liquid scintillation. Radioactive measurements were converted to picomoles of product by using the specific activity of substrate. Blank values obtained from controls lacking cell proteins were subtracted from the experimental values. PI-PLC activity and PC-PLC activity were expressed as picomoles DAG producedlmg protein.
In vitro acidic and neutral SMase analysis
Aliquots of 6x I0 6 cells/ml were treated for the indicated times with AACOCF3 (10 f.lM) or Dex (10. 7 M) in presence or in absence of the PI-PLC inhibitor U73l22 or the endolysosomial inhibitor monensin (10 f.lM). Treatments were stopped by immersion of samples in methanol/dry ice (-70°C) for 10 seconds, followed by centrifugation at 4°C in a microfuge. Cells were washed, and pellets were resuspended in 200 ul of 0. After centrifugation the aqueous phase was extracted twice more with chloroform. The organic phases, obtained in the different extraction steps, were collected and washed once with I rnl of chlorofonn:methanol: water (3:48:47, by vol), to remove totally free radioactive phosphorylcholine, the other hydrolysis product of sphingomyelin. The aqueous phases were collected, transferred to scintillation vials and content measured by liquid scintillation counting. The counts/min represented the choline phosphate generated from SM hydrolysis. The percentage hydrolysis of substrate was calculated from the ratio of counts of the upper phase to the total counts added in the system x 100. The hydrolysis of SM was expressed as pmol SM hydrolysed/h/mg protein.
Ceramide mass measurement (DAG kinase assay)
Aliquots of 5x 10 6 cells were suspended in I ml of RPMI 1640 medium supplemented with 10% FCS, 2 mM glutamine and antibiotics, and treated for the indicated times with Dex in the presence or absence of AACOCF3. Treatment was stopped by immersion of samples in methanol/dry ice (-70°C) for 10 sec followed by centrifugation at 4°C in a microfuge. To measure ceramide levels, pellets were dissolved in a buffer containing Tris-HCI 20 mM pH 7.4, I f.lM PMSF, 10 f.lM leupeptin, 10 f.lM pepstatin, I f.lM aprotinin. After the incubation time (5 min at 4°C), cells were sonicated (5W, 80 % output, I min and 50 sec, alteming 10 sec sonication and 10 sec pause) with a Vibracell sonicator (Sonic and Materials Inc., Danbury, CT). Protein concentration of cell Iysates was determined through the Pierce Micro SCA assay kit (Pierce, Rockford, III, USA), with bovine serum albumine standards. Lipids were extracted by the sequential addition of400 f.ll methanol, 500 ul chloroform and 200 ul water. Samples were stirred for 2 min on a vortex-mixer and centrifuged at 10,800 g for 10 min. The extraction and centrifugation steps were repeated twice. The organic phases, obtained from different extraction steps were collected, dryed under nitrogen, and then incubated with Escherichia coli diacylglycerol kinase (DAG kinase assay kit) and 32P-ATPgamma (spec. act. 3 Ci/mmol, Amersham, Little Chalfont, UK). Ceramide-lphosphate was then isolated by thin layer chromatography using CHCl/CHPH/CH 3COOH (65/15/5, vol/vol/vol) as solvent. Authentic ceramide from bovine brain (Ceramide Type III, non-hydroxy fatty acid ceramides; Sigma) was identified by autoradiography at Rf=0.25. Specific radioactivity of ceramide-J-phosphate was determined by scintillation counting of corresponding spots scraped off the gel. Quantitative results for ceramide production were obtained by comparing the experimental values to a linear curve of the ceramide standards and are expressed as pmol of ceramide-I-phosphate/l 0 6 cells.
CPP32 activity assay
The CPP32/Caspase-3 protease activity was assayed by using the ApoAlert CPP32 Caspase-3 Colorimetric Assay Kit (Clontech Laboratories, Inc, Palo Alto, CA), based on spectrophotometric detection at 405 nm of the chromophore p-nitroanilide (PNA) after cleavage from the labelled substrate Asp-Glu-Val-Asp (DEVD)-pNA. The units of protease activity can be quantified using a standard curve established with the chromogenic molecule. Briefly, cells (2x10 6/ml), treated with Dex (l0-7M) for 6 h in presence or in absence of inhibitors, were collected and resuspended in a lysis buffer. Cellular lysates were then incubated in a microplate in presence of conjugated protease substrate for I h at 37°C and then analyzed using a 96-well plate reader. To verify that the detected signal was attributable to protease activity, the effect ofthe irreversible CPP32 inhibitor DEVD-FMK on the Dex-induced caspase activity was also tested. Thus, cell lysates from AACOCF and Dex-induced samples were treated with CPP32 inhibitor before incubation with the substrate, according to the manufacturer's instructions. Caspase activity was expressed as nanomoles pNNI 0 6 cells.
Statistical analysis
Statistical analysis of data was performed by using one-way analysis of variance ANOVA followed by the Student's t test for paired, or by the correlation analysis (Prism 3.0 GraphPad Software, San Diego, Ca). P value less than 0.05 was used as the significance criterion.
RESULTS
Dex-induced apoptosis and PLA 2 inhibition is antagonised by RU486
It has been previously reported, by different experiments, that Dex is able to induce apoptosis in mouse thymocytes and to inhibit PLA z activity (16) . In the attempt to correlate the effect of pre-treatment with the glucocorticoid antagonist RU486 on Dex-mediated induction of apoptosis and inhibition of PLA z activity, thymocytes were treated with Dex alone or Dex plus RU486 and both apoptosis and AA release were evaluated ( Fig. lA-B ). As expected, treatment with Dex caused a significative apoptosis increment versus control (P<O.O I) and an significant reduction of AA basal levels (P<0.05). Fig. IA-B shows that Dex-induced thymocyte apoptosis and the rapid cPLA z inhibition were receptor-mediated as preincubation of thymocytes for I h with the glucocorticoid receptor antagonist RU486 (I flM) significantly prevented either Dex-induced apoptosis or AA decrease (P<0.05 and P<O.O I respectively). 
Dex and AACOCF3 induce thymocyte apoptosis and inhibition ofcPLA2 activity
To analyse the possible role of PLA o activity inhibition on thymocyte apoptosis, we firstly performed experiments to test the possible effect of different PLA z inhibitors on apoptosis. In particular, we observed that treatment of cultured mouse thymocytes for 18 h with Dex (10-7M), or the cPLA z inhibitors AACOCF3 (10 flM) or PACOCF3 (10 flM), induced significant thymocyte apoptosis (P<O.Ol; P=O.OI respectively) ( Fig. 2A) , whereas the apoptosis percentages were not significantly different from control value in presence ofthe sPLA z inhibitor, pBPB (20 flM) or the iPLA 2 inhibitor, BEL (5 flM). When thymocytes were incubated with the potent and selective cPLA 2 inhibitor AACOCF3, poor effects on thymocyte apoptosis and AA release were observed when concentrations were lower than 10 flM (data not shown). Indeed, a concentration of 10 flM AACOCF3 was then selected in all the experiments, because, as shown in Fig. 2A , it caused a significant induction of thymocyte apoptosis (P=O.O 1) and a significant inhibition of cPLA z activity at all the analyzed times (P<0.05) (Fig.  2B) . In particular, Dex-and AACOCF3-induced apoptosis was associated with a rapid inhibition, within a few minutes, of thymocyte cPLA z activity, while no effect on the activity of the sPLA z was "" e 300 ... observed (data not shown).
Effect ofDex on AA release from living thymocytes
As shown in Fig. 3 , control pre-labeled thymocytes basally released significant 3H-AA levels during the I to 60 min time frame. This result is consistent with the high cPLA 2 basal activity showed in untreated mouse thymocytes (see above). The treatment of thymocytes with 10·7M Dex, as expected, led to a marked reduction of AA release which was detectable yet at I min and was higher than 30% reduction at all time points (mean 34.67±3.97).
AACOCF3
induces activation of a phosphatidylinositol-specific phospholipase C~(
PI-PLC) and acidic sphingomyelinase (aSMase)
We have previously demonstrated that. Dexinduced thymocyte apoptosis involves the sequential activation of PI-PLC~and the aSMase (5) . Considering the similar effects of Dex and AACOCF3 on cPLA 2 activity and thymocyte apoptosis, we decided to verify whether thymocyte treatment with cPLA 2 inhibitor was able to activate the same signalling pathway too. In Fig. 4A , we show that thymocyte pretreatment for 30 min with U73122 (2.5~M), a specific inhibitor of PI-PLCã ctivation, or Monensin (I 0~M), able to inhibit the aSMase, completely reversed the apoptotic activity of both Dex (P<0.05 and P<O.O I respectively) and AACOCF3 on mouse thymocytes (P<0.05 and A P<O.O 1 respectively). In order to further characterize the involvement of Pl-PLC~and aSMase in AACOCF3-induced thymocyte apoptosis, we performed experiments to evaluate both enzyme activities in thymocytes following Dex and AACOCF3 treatment for different periods of time. To this end, cell extracts from control, Dex (l0· 7 M) and AACOCF3 (l0 
AACOCF3 induces ceramide generation
In order to confirm whether the ceramide level M) treated thymocytes, were tested for PI-PLCõ r PC-PLC activity by analysing their ability to hydrolyse 1 4 C_PI or 14C_PC vesicles, respectively, to generate diacylglycerol (DAG) as described in the Materials and Methods section. The results of these experiments, reported in Fig. 4B demonstrate that both Dex and AACOCF3 induced a rapid and statistically significant activation of PI-PLC activity (P<O.Ol and P<0.05 respectively), that peaked at 5 min, followed by a gradual decline. In addition, thymocyte co-treatment with U73l22 completely abolished AACOCF3 and Dex stimulation of PI-PLC activity. On the other hand, we did not observe any modification of PC-PLC activity following Dex or AACOCF3 thymocyte treatment.
To test the effects of AACOCF3 and Dex, as a control, on neutral and acidic SMase activity, thymocytes were treated for the indicated times with AACOCF3 (l 0~M) or Dex (l 0. 7 M) in the presence or absence of the PI-PLC inhibitor U73l22 (2.5~M) or the endolysosomial inhibitor Monensin (10~M). At the end of the treatments, cells were analysed for the determination of the acid and neutral SMase as described in the Materials and Methods section. The results of these experiments clearly demonstrate a time-dependent activation of the acidic SMase as a consequence of AACOCF3 and Dex thymocyte treatment even if the kinetics appeared slightly different (Fig. 4C ). In particular, AACOCF3, like Dex, induced a rapid SM hydrolysis which was significantly higher than untreated samples, being evident just at 1 min, peaked at 5 min and then rapidly declined. The AACOCF3 effect appeared more prolonged when compared to Dex. Indeed, the AACOCF3-induced SM hydrolysis remained at high levels in the time range between 5 and 30 min, after which it gradually declined. AACOCF3-treated sample values were significantly different from the corresponding control values at all the analyzed times (P<0.05). No effects were observed on the activity of the nSMase in the experimental timeframe (data not shown). In the same figure, it is also reported that pre-treatment of thymocytes with both U73l22 and Monensin completely abolished AACOCF3 and Dex stimulation of the aSMase activity. increase observed in vitro on thymocytes treated with Dex could also be obtained in presence of AACOCF3, we analyzed the ceramide levels of AACOCF3-treated thymocytes (10 IlM) for 15 min, that is the timeframe in which the Dex-driven ceramide generation was maximal. Treatment of thymocytes with AACOCF3 resulted in significant increase of ceramide generation (P=O.O 1), as detected by TLC analysis of phospholipids extracted from cells and subjected to DAG kinase assay (Fig.  5 ). The AACOCF3-induced ceramide generation shared a similar trend with Dex.
AACOCF3 induces caspase 3 activation
To verify that AACOCF3-induced thymocyte apoptosis involves caspase activation cascade, a characteristic event of Dex-induced thymocyte apoptosis, we tested the apoptotic effect of AACOCF3 (10 IlM), and Dex (10-7 M) as a control, in the presence of the caspase 3 inhibitor Z-DEVD-fmk. The results of these experiments, reported in Fig. 6A , clearly show the ability of the caspase 3 inhibitor to reduce both Dex-and AACOCF3-induced thymocyte programmed cell death in a significant manner (P < 0.05). We also measured caspase 3 activity in cell extracts from cultured thymocytes in basal condition or following AACOCF3 and Dex treatment for 6 h. The results, reported in Fig. 6B clearly demonstrate the ability of AACOCF3 and Dex to significantly augment caspase 3 activity in mouse thymocytes (P < 0.01 and P < 0.05 respectively).
DISCUSSION
In the present study, we report that Dex, a synthetic GCH, induces a rapid (within few minutes) inhibition of cPLA 2 activity that could be of physiological relevance in glucocorticoid modulation of survival, in analogy with the role of prostaglandin generation to support cancer cell proliferation (17) . The cPLA z inhibitory effect of Dex was totally attributable to its interaction to the GR, the GR antagonist RU486 being able to totally abrogate both cPLA z inhibition and apoptotis.
Thymocyte cPLA? inhibition correlates with apoptosis induction and may be part of the complex intracellular signals which are GCH-regulated during thymocyte development. In fact, the rapid pharmacological inhibition of cPLA z activity, by AACOCF3 and PACOCF3, induced apoptosis which was similar to Dex in term of kynetics. Of note, the sPLA z inhibitor (pBPB) or the iPLA 2 inhibitor (BEL), were unable to induce thymocyte 5 11M) . a specific inhibitor of the PI-PLC~, or Monensin (10 11M) . a specific inhibitor ofaSMase. before treatment with Dex (10-7 M) or AACOCF3 (10 1lA1J . At the end ofthe incubation period (18 h) . apoptosis was evaluated. (B) Thymocytes were treatedfor the indicated times in absence or in presence ofDex (10-7 M) or AACOCF3 (10 11M) . and in absence or in presence U73122 (2.5 11M) . apoptosis, suggesting a specific activity of the cPLA 2 in thymocyte survival. With the aim of analysing arachidonic acid release in the living cells and its modifications after treatment with dexamethasone, experiments were performed by pre-incorporating radioactive free arachidonic acid in primary cultured thymocytes and measuring the release of arachidonic acid by the thymocytes in the first hour of dexamethasone treatment. The results confirm that control thymocytes basally released a relevant AA level in accordance with the constitutively activated cPLA 2 in these cells. Furthermore, the obtained data show that dexamethasone treatment, as expected, was also able to significantly inhibit AA release in the extracellular medium at the different time points (range: 1-60 min).
Moreover, as previously observed in DEXtreated thymocytes (5), cPLA 2 inhibitors were able to induce the sequential activation of the PI-PLC, aSMase, ceramide generation and caspase activation, suggesting that the cPLA 2 inhibitors and Dex can trigger the same apoptotic pathway.
AACOCF3-induced thymocyte apoptosis seems to be dependent on a rapid inhibition of cPLA 2 activity. In fact, AA levels were significantly lowered 5-15 minutes after Dex and AACOCF3 treatment.
Since the specific inhibitor of cPLA 2 AACOCF3, like Dex, was able to induce thymocyte apoptosis and to inhibit AA release, we investigated whether the apoptotic signaling induced by AACOCF3 was similar to the Dex-induced one.
In order to confirm the possible involvement of PI-PLCy and of the acid SMase in the AACOCF3induced apoptotic signalling, we observed that the percentages of Dex-and AACOCF3-induced apoptosis are reduced by thymocyte pre-treatment with a specific inhibitor of the PI-PLCy (U73122) and with the inhibitor ofaSMase (Monensin). In fact, PI-PLCy and aSMase have a very important role in mediating programmed cell death, their activation being required for different apoptotic signals.
Our findings indicate that in AACOCF3-induced apoptosis the diacyl-glycerol (DAG) generation gradually increased in a time-dependent manner, being evident as early as 1 min after AACOCF3 stimulation and peaking at 5 minutes. The increase of DAG levels was due to PI-PLCy-mediated hydrolysis of PI, as revealed by enzymatic assay in thymocyte extracts.
Notably, no detectable PC-PLC activity was observed in thymocyte culture after AACOCF3 and Dex treatment. Accordingly, the specific inhibitor of PI-PLCy (U73122) was able to totally abolish the AACOCF3-induced DAG generation.
Since an increase ofPI-PLC activity is required for sequential aSMase activation, we next investigated the involvement of the aSMase in the AACOCF3mediated apoptotic signal.
As previously demonstrated, Dex-induced aSMase activity was prevented by the treatment with Monensin, an endolysosomotropic agent capable of neutralizing the acidic pH in the endolysosomal compartments, thus countering the activation of lysosomal enzymes, including aSMase (5) .
Interestingly, an almost complete inhibition of Dex-or AACOCF3-induced aSMase activity was achieved using the U73122 inhibitor, since it blocks the down-stream ceramide generation, thus preventing the DAG release consequent to the PI-PLCy activity. In the present study, we also observed that ceramide was rapidly released during AACOCF3-induced thymocyte apoptosis and this result is in accordance with the high levels of aSMase activation which are induced by AACOCF3 as well as by Dex.
Several of the biochemical events that contribute to apoptotic cell death have recently been elucidated; moreover, an important role has been proposed for a number of different proteases, including serine proteases (19) . Among them, caspase-3 is capable of autocatalysis as well as cleaving and activating other members of the caspase family, when cells are signaled to undergo apoptosis in response to serum withdrawal, activation of CD95 or treatment with ionizating radiations.
Similarly to Dex, AACOCF3 was able to induce caspase-3 activity, which was in tum critical to apoptosis induction, being a caspase-3 specific inhibitor able to prevent AACOCF3 induced apoptosis.
These results indicate thatAACOCF31ead to similar biochemical events involved in Dex-induced apoptosis signaling. The effect of cPLA 2 inhibitor suggests the important role of cPLA 2 in thymocyte physiology. Several studies demonstrate that intracellular cPLA 2 is a widely distributed enzyme which has been found in platelets, renal mesangial cells, macrophages and leukaemia cell lines. One notable exception is mature T and B lymphocytes that do not contain cPLA 2 , thus suggesting that the expression of cPL~may be incompatible with the function of mature lymphocyte development. In contrast, cPLA 2 is expressed and activated in thymocytes and immature B lymphocytes (13) and its inhibition mediates anti-inflammatory effects (19) . Moreover, it has been demonstrated that the Ca 2 +-independent PLA 2 isoform is expressed in human monocytes, B cells and T cells and has a dramatic role in regulation of lymphocyte growth (2).
However, cPLA 2 contribution in regulating T cell proliferation is unclear. In fact, several observations suggest that human Jurkat T cells express the mRNA encoding for two secretory and two cytosolic (Ca 2 +independent and Ca't-dependent) isoforms of PLA 2 and, of these, only three forms (the two secretory and the cytosolic Ca 2+-independent ones) are implicated in T cell blastogenesis ( 14) . Boilard and Surette have identified type IV PLA 2 in human T-Iymphocyte (20) , further indicating that different PLA 1 molecules may operate in the cell.
-Further studies will be carried out to address the possible specific roles of the different PLA 1 isoforms in the control of cell growth.
with an increased rate of arachidonate-phospholipid remodeling. Lack of involvement of group IV and group VI phospholipase A2 in remodeling and increased susceptibility of proliferating T cells to CoA-independent transacyclase inhibitor-induced apoptosis. J Bioi Chern 2001; 276:17568-75.
